CD79A and COVID-19: Here, we step further by determining the proportion of patients with IgA-dominant humoral response in defending against SARS-CoV-2 and evaluate the potential role of anti-SARS-CoV-2 RBD IgA in pathology, rather than protection, in a severe COVID-19 patient with concurrent IgAN.